Evidence map›Paper›PMID 40471340›Full record

ArticleEuropean spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society2026

Treatments and outcomes of primary and metastatic spinal angiosarcoma patients: study of 29 consecutive cases.

Haoran Lin, Ting Wang, Jian Sun, Na Cui, Wei Xu, Jian Jiao, Xinghai Yang, Haifeng Wei, Tielong Liu, Chenglong Zhao and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Haoran Lin *Department of Orthopedic Oncology, Shanghai Changzheng Hospital, Shanghai, China.
Ting Wang *Department of Orthopedic Oncology, Shanghai Changzheng Hospital, Shanghai, China.
Jian Sun *Department of Orthopedic Oncology, Shanghai Changzheng Hospital, Shanghai, China.
Na CuiDepartment of Pathology, Shanghai Changzheng Hospital, Shanghai, China.
Wei XuDepartment of Orthopedic Oncology, Shanghai Changzheng Hospital, Shanghai, China.
Jian JiaoDepartment of Orthopedic Oncology, Shanghai Changzheng Hospital, Shanghai, China.
Xinghai YangDepartment of Orthopedic Oncology, Shanghai Changzheng Hospital, Shanghai, China.
Haifeng WeiDepartment of Orthopedic Oncology, Shanghai Changzheng Hospital, Shanghai, China.
Tielong LiuDepartment of Orthopedic Oncology, Shanghai Changzheng Hospital, Shanghai, China.
Chenglong ZhaoDepartment of Orthopedic Oncology, Shanghai Changzheng Hospital, Shanghai, China.
Jianru XiaoDepartment of Orthopedic Oncology, Shanghai Changzheng Hospital, Shanghai, China.
Zhipeng WuDepartment of Orthopedic Oncology, Shanghai Changzheng Hospital, Shanghai, China. eaglewzp@163.com.

Funding

Jianru Xiao 82173028Ting Wang 81874180Zhipeng Wu 81972505
6 · The paper itself

Abstract

purposeSpinal angiosarcoma (AS) is rare, with limited understanding of its therapeutic outcomes and prognostic factors. This study aimed to evaluate the impact of surgery and adjuvant treatments on the prognosis of patients with primary and metastatic spinal AS, as well as potential prognostic factors affecting spinal AS patients.

methodsA retrospective review was conducted on 29 consecutive patients with spinal AS at our center from 2014 to 2023. We divided spinal AS patients into primary and metastatic groups, and analyzed the effects of surgical methods, along with adjuvant chemotherapy and radiotherapy, in the prognosis of the two groups. Additionally, the prognostic factors for progression-free survival (PFS) and overall survival (OS) were analyzed by using the univariate and multivariate analyses in spinal AS patients.

resultsIn isolated primary spinal AS patients, the 5-year OS and PFS rates were 47.9% and 44.9%, respectively. While the 5-year OS and PFS rates were both 0% in metastatic patients. Total tumor resection improved the OS of primary group (P = 0.023), but had limited impact on the prognosis of the metastatic group. Chemotherapy improved the OS of spinal AS patients (P = 0.047), and showed possible trend on improving prognosis in both groups though without statistical significance. Multivariate analysis confirmed that involved segments, surgical protocol, and preoperative C-reactive protein-to-albumin ratio (CAR) were independent prognostic factors for PFS, while preoperative metastasis, tumor size, and preoperative neutrophil-to-lymphocyte ratio (NLR) were the independent prognostic factors for OS in spinal AS patients.

conclusionTotal tumor resection is recommended for primary spinal AS patients without metastasis. Chemotherapy may improve the OS of all spinal AS patients. Besides tumor size and range, metastasis, and surgical methods, inflammatory indicators including NLR and CAR may also function in the prognostic prediction of spinal AS patients.

Indexed as

HemangiosarcomaSpinal NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesTreatment OutcomeAngiosarcomaChemotherapyPrognostic factorSpineSurgery

Identifiers

PMID40471340

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.